1
|
The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene.
|
Cancer Res
|
2002
|
1.23
|
2
|
Side effects of chaperone gene co-expression in recombinant protein production.
|
Microb Cell Fact
|
2010
|
1.01
|
3
|
The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation.
|
Biomaterials
|
2010
|
0.90
|
4
|
Induction of G(2)/M arrest and inhibition of c-myc and p53 transcription by WP631 in Jurkat T lymphocytes.
|
Biochem Pharmacol
|
2002
|
0.88
|
5
|
Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide.
|
Nanomedicine (Lond)
|
2010
|
0.87
|
6
|
A new bisintercalating anthracycline with picomolar DNA binding affinity.
|
J Med Chem
|
2005
|
0.86
|
7
|
Modular protein engineering in emerging cancer therapies.
|
Curr Pharm Des
|
2009
|
0.86
|
8
|
Rehosting of bacterial chaperones for high-quality protein production.
|
Appl Environ Microbiol
|
2009
|
0.84
|
9
|
Bacterial cell factories for recombinant protein production; expanding the catalogue.
|
Microb Cell Fact
|
2013
|
0.84
|
10
|
Fast electrochemical detection of anti-HIV antibodies: coupling allosteric enzymes and disk microelectrode arrays.
|
Anal Chim Acta
|
2009
|
0.83
|
11
|
Internalization and kinetics of nuclear migration of protein-only, arginine-rich nanoparticles.
|
Biomaterials
|
2010
|
0.83
|
12
|
Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A.
|
Appl Microbiol Biotechnol
|
2015
|
0.81
|
13
|
A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631.
|
Eur J Biochem
|
2003
|
0.81
|
14
|
Enhanced response to antibody binding in engineered beta-galactosidase enzymatic sensors.
|
Biochim Biophys Acta
|
2002
|
0.81
|
15
|
Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles.
|
Int J Nanomedicine
|
2012
|
0.81
|
16
|
Peptide-assisted traffic engineering for nonviral gene therapy.
|
Drug Discov Today
|
2008
|
0.81
|
17
|
DnaK/DnaJ-assisted recombinant protein production in Trichoplusia ni larvae.
|
Appl Microbiol Biotechnol
|
2009
|
0.80
|
18
|
Analytical approaches for assessing aggregation of protein biopharmaceuticals.
|
Curr Pharm Biotechnol
|
2011
|
0.79
|
19
|
Nanoparticulate architecture of protein-based artificial viruses is supported by protein-DNA interactions.
|
Nanomedicine (Lond)
|
2011
|
0.79
|
20
|
Protein aggregation and soluble aggregate formation screened by a fast microdialysis assay.
|
J Biomol Screen
|
2010
|
0.78
|
21
|
RGD-based cell ligands for cell-targeted drug delivery act as potent trophic factors.
|
Nanomedicine
|
2012
|
0.78
|
22
|
In vivo architectonic stability of fully de novo designed protein-only nanoparticles.
|
ACS Nano
|
2014
|
0.78
|
23
|
Engineering of Escherichia coli beta-galactosidase for solvent display of a functional scFv antibody fragment.
|
FEBS Lett
|
2003
|
0.77
|
24
|
Non-amyloidogenic peptide tags for the regulatable self-assembling of protein-only nanoparticles.
|
Biomaterials
|
2012
|
0.77
|
25
|
Screening HIV-1 antigenic peptides as receptors for antibodies and CD4 in allosteric nanosensors.
|
J Mol Recognit
|
2009
|
0.76
|
26
|
Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria.
|
Biofabrication
|
2016
|
0.76
|
27
|
Analysing the contribution of nucleic acids to the structure and properties of centric heterochromatin.
|
Genetica
|
2003
|
0.76
|
28
|
Recombinant protein materials for bioengineering and nanomedicine.
|
Nanomedicine (Lond)
|
2014
|
0.76
|
29
|
A novel bio-functional material based on mammalian cell aggresomes.
|
Appl Microbiol Biotechnol
|
2015
|
0.76
|
30
|
Engineering tumor cell targeting in nanoscale amyloidal materials.
|
Nanotechnology
|
2016
|
0.75
|
31
|
Cross-system excision of chaperone-mediated proteolysis in chaperone-assisted recombinant protein production.
|
Bioeng Bugs
|
2009
|
0.75
|
32
|
Improved performance of protein-based recombinant gene therapy vehicles by tuning downstream procedures.
|
Biotechnol Prog
|
2013
|
0.75
|
33
|
Integrated approach to produce a recombinant, His-tagged human α-galactosidase A in mammalian cells.
|
Biotechnol Prog
|
2011
|
0.75
|
34
|
Effect of the DnaK chaperone on the conformational quality of JCV VP1 virus-like particles produced in Escherichia coli.
|
Biotechnol Prog
|
2014
|
0.75
|
35
|
Engineered biological entities for drug delivery and gene therapy protein nanoparticles.
|
Prog Mol Biol Transl Sci
|
2011
|
0.75
|